Investment firm hurt by Valeant stake says CEO is retiring
NEW YORK - The CEO of a firm with the largest stake in troubled Valeant Pharmaceuticals is retiring after punishing losses due to that investment.
NEW YORK - The CEO of a firm with the largest stake in troubled Valeant Pharmaceuticals is retiring after punishing losses due to that investment.